2024年6月最新影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Expert Opinion On Drug Safety EXPERT OPIN DRUG SAF （此期刊被最新的JCR期刊SCIE收录） LetPub评分 6.3
52人评分
我要评分
声誉 7.6 影响力 5.1 速度 6.9 | |||||||||||||||||||||
| 期刊ISSN | 1474-0338 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1744-764X | |||||||||||||||||||||
| 2023-2024最新影响因子 （数据来源于搜索引擎） | 3 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2024年3月26日：2.699 | |||||||||||||||||||||
| 2023-2024自引率 | 3.30%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 3.6 | |||||||||||||||||||||
| JCI期刊引文指标 | 0.62 | |||||||||||||||||||||
| h-index | 62 | |||||||||||||||||||||
| CiteScore （ 2024年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.tandfonline.com/loi/ieds20#.V48bfkz9cSQ | |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/eods | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Expert Opinion On Drug Safety的语言要求，还能让Expert Opinion On Drug Safety编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Expert Opinion On Drug Safety编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ | |||||||||||||||||||||
| 出版商 | Taylor and Francis Ltd. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-药学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Bimonthly | |||||||||||||||||||||
| 出版年份 | 2002 | |||||||||||||||||||||
| 年文章数 | 155点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 14.18% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 67.10% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2023-2024年最新版） | WOS分区等级：2区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1474-0338%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 较慢,6-12周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Expert Opinion On Drug Safety顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Interstitial pneumonitis associated with EGFR/ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study Author: Ma, Zhuo; Pei, Jie; Zhang, Yi; Li, Hao; Sun, Dan; Zhang, Yuhui; An, Zhuoling Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. 22, Issue 3, pp. 237-242. DOI: 10.1080/14740338.2022.2110235 PubMed DOI |
| 2. | Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study Author: Wu, Junyan; Huang, Jianxiang; Zhu, Jianhong; He, Zhichao; Chen, Mengting; Gao, Siyuan; Liang, Dan; Yu, Xiaoxia; Lu, Chengyu Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. 22, Issue 3, pp. 231-235. DOI: 10.1080/14740338.2022.2110234 PubMed DOI |
| 3. | Lack of association between febrile seizures and vaccines containing diphtheria, tetanus, and acellular pertussis in Chinese children Author: Xu, Lu; Li, Ning; Zhang, Liang; Ma, Rui; Fang, Ting; Liu, Zhike; Zhan, Siyan Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. 22, Issue 3, pp. 253-258. DOI: 10.1080/14740338.2022.2116000 PubMed DOI |
| 4. | Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis Author: Leung, John Hang; Tai, Yun-Sheng; Wang, Shyh-Yau; Tsung-Chin, Ho; Yip Fion, Hei-Tung; Chan, Agnes L. F.; Yu-Chen, Hsu Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. 22, Issue 3, pp. 243-252. DOI: 10.1080/14740338.2022.2116001 PubMed DOI |
| 5. | Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study Author: Chen, Chen; Wu, Bin; Zhang, Chenyu; Xu, Ting Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. 22, Issue 3, pp. 259-266. DOI: 10.1080/14740338.2022.2120609 PubMed DOI |
| 6. | Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors Author: Zhai, Yinghong; Hu, Fangyuan; Shi, Wentao; Ye, Xiaofei; Xu, Jingfang; Guo, Xiaojing; Cao, Yang; He, Jia; Xu, Feng Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2023.2204226 PubMed DOI |
| 7. | PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS) Author: Wang, Qiaoyun; Xiao, Fengjiao; Zeng, Yanbin; Zhu, Qiaoling; Zhang, Haixia Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2023.2203483 PubMed DOI |
| 8. | Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database Author: Wang, Lin-Yu; Liao, Liu-Feng; Lei, Cai-Lu; Wu, Qiong; Guo, You-Jia; Li, Yan Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2023.2203487 PubMed DOI |
| 9. | Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports Author: An, Pengjiao; Liu, Xin; Zhang, Bo Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2023.2204227 PubMed DOI |
| 10. | High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database Author: Ma, Pan; Tian, Hao; Shi, Qiuling; Liu, Ruixiang; Zhang, Yi; Qi, Xiaowei; Chen, Yongchuan Journal: EXPERT OPINION ON DRUG SAFETY. 2023; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2023.2204228 PubMed DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
